Affimed N.V. (NASDAQ:AFMD) Q1 2024 Earnings Conference Call June 12, 2024 8:30 AM ET Company Participants Alexander Fudukidis – Head, IR Andreas Harstrick – CMO and Interim CEO Michael Wolf – VP, Finance Conference Call Participants Srikripa Devarakonda - Truist Securities Daina Graybosch - Leerink Partners Maury Raycroft - Jefferies Li Watsek - Cantor Fitzgerald Yale Jen - Laidlaw & Company Bradley Canino - Stifel, Nicolaus & Company Operator Good day, everyone and welcome to Affimed's First Quarter 2024 E ...

HARNESSING THE POTENTIAL OF THE INNATE IMMUNE SYSTEM FOR ONCOLOGY NASDAQ: AFMD Q1 2024 Business & Financial Update Forward-Looking Statements This presentation and the accompanying oral commentary contain “forward-looking” statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying oral commentary, including statements regarding our future financial condition, business strategy and plans and objecti ...

Exhibit 99.1 Affimed N.V. Unaudited consolidated statements of comprehensive loss (in € thousand) | --- | --- | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------|-------|----------------------------------|----------------------------| | | Note | For the three March \n2024 | months ended 31 \n2023 | | Revenue | 3 | 155 | 4,510 | | Other income – net | | 177 | 410 | | Research and development ex ...

- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) - - AFM28 shows single agent efficacy with 2 CR/CRi and 3 stable disease (SD) in 6 patients treated at dose level of 300 mg weekly - Acimtamig (AFM13) combination with AlloNK® (AB-101) natural killer (NK) cells: Recruitment in cohorts 1 and 2 completed. In the first 7 treatment refractory Hodgkin Lymphoma (HL) patients, an ORR of 85.7% observed, with 4 CRs and ...

- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) - - AFM28 shows single agent efficacy with 2 CR/CRi and 3 stable disease (SD) in 6 patients treated at dose level of 300 mg weekly - Acimtamig (AFM13) combination with AlloNK® (AB-101) natural killer (NK) cells: Recruitment in cohorts 1 and 2 completed. In the first 7 treatment refractory Hodgkin Lymphoma (HL) patients, an ORR of 85.7% observed, with 4 CRs and ...

MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2024 results and corporate update on Wednesday, June 12, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" se ...

MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2024 results and corporate update on Wednesday, June 12, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the “Webcasts” s ...

Affimed N.V. (AFMD) surged 68.5% after the company reported follow-up efficacy data from the EGFR wild-type (EGFRwt) cohort and initial clinical efficacy data from the EGFR mutant (EGFRmut) cohort of the ongoing early to mid-stage study of AFM24 to treat non-small cell lung cancer (NSCLC) patients.The phase I/IIa AFM24-102 study is evaluating AFM24 in combination with Roche’s (RHHBY) immuno-oncology drug, Tecentriq (atezolizumab), in heavily pre-treated NSCLC patients.Please note that the company first repo ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Affimed N.V. (AFMD) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Affimed N.V. is a member of the Medical sector. This group includes 1046 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank includes 16 dif ...

In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing for more than 7 months and progression free survival (PFS) was 5.9 monthsObjective responses were also seen in 4 of 13 response-evaluable EGFR mutant (EGFRmut) NSCLC patients confirming the activity of AFM24 and atezolizumab in heavily pretreated NSCLC patientsIn both NSCLC cohorts, the combination therapy show ...